Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 643

Results For "AI"

6947 News Found

Abbott launch room-temperature carbetocin in India for Postpartum Haemorrhage
News | September 01, 2021

Abbott launch room-temperature carbetocin in India for Postpartum Haemorrhage

PPH is associated with almost 20 per cent of maternal mortality in India


Zymo Research receives CE Mark for new Covid-19 SafeCollect kits
Drug Approval | September 01, 2021

Zymo Research receives CE Mark for new Covid-19 SafeCollect kits

Self-collection devices designed for ease of use and safety


Metropolis Healthcare opens new testing centre in Thalassery, Kerala
Healthcare | September 01, 2021

Metropolis Healthcare opens new testing centre in Thalassery, Kerala

The lab will offer about 4,000 different tests ranging from basic to high-end molecular diagnostic tests


Dr. Reddy's announce launch two drugs in the US market
News | August 31, 2021

Dr. Reddy's announce launch two drugs in the US market

Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, USP are available in one strength of 5 mg/2.5 mg capsules in bottle count sizes of 100


US FDA clears InnoCare’s clinical trial of pan-TRK Inhibitor ICP-723
Drug Approval | August 31, 2021

US FDA clears InnoCare’s clinical trial of pan-TRK Inhibitor ICP-723

The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers


US FDA grants Lantern Pharma additional Orphan Drug tag for LP-184
Biotech | August 31, 2021

US FDA grants Lantern Pharma additional Orphan Drug tag for LP-184

The drug is also intended for the treatment of glioblastoma multiforme


Sun Pharma to commercialise Winlevi in the US and Canada
News | August 31, 2021

Sun Pharma to commercialise Winlevi in the US and Canada

Acne affects up to 50 million Americans annually. The last FDA approval of an acne drug with a new MOA occurred nearly 40 years ago


Sanofi’s Dupixent pivotal trial meets all primary and secondary endpoints for treatment of atopic dermatitis
Biotech | August 31, 2021

Sanofi’s Dupixent pivotal trial meets all primary and secondary endpoints for treatment of atopic dermatitis

Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old


Vivo Bio Tech enters long-term contract with Bio E
Biotech | August 30, 2021

Vivo Bio Tech enters long-term contract with Bio E

The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years


Union Minister Sonowal announces major plans for promoting Ayush in NE
Policy | August 30, 2021

Union Minister Sonowal announces major plans for promoting Ayush in NE

A sum of Rs 70 crores and Rs 10 crores for a new Ayurvedic college in Assam and upgradation of the ayurvedic college in Guwahati respectively